Last reviewed · How we verify
Dovobet® ointment
Dovobet combines calcipotriene (a vitamin D analogue) and betamethasone dipropionate (a corticosteroid) to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis.
Dovobet combines calcipotriene (a vitamin D analogue) and betamethasone dipropionate (a corticosteroid) to reduce skin inflammation and normalize keratinocyte differentiation in psoriasis. Used for Plaque psoriasis (topical treatment).
At a glance
| Generic name | Dovobet® ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Combination topical agent (vitamin D analogue + corticosteroid) |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist, promoting differentiation and reducing proliferation of keratinocytes, while betamethasone dipropionate provides potent anti-inflammatory effects through glucocorticoid receptor activation. Together, these complementary mechanisms address both the hyperproliferation and inflammatory components of psoriatic plaques.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Skin irritation or burning at application site
- Pruritus
- Erythema
- Local skin atrophy (with prolonged use)
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (PHASE2)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
- A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris (PHASE2)
- A Vasoconstriction Study With LEO 90100 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |